" class="no-js "lang="en-US"> Vincent Charlon - Medtech Alert
Tuesday, April 16, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Vincent Charlon

Vincent Charlon

About Vincent Charlon

30+ years of experience in global pharmaceutical development
of which 8 years as CEO of a clinical CRO and
15 years as CEO of three successive biotech companies

Related Story

Company Releases

 Tollys and Gustave Roussy Enter into New Research Agreement | Pharmtech Focus

Tollys and Gustave Roussy Enter into New Research Agreement

March 7 2022

Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a synthetic toll-like […]

Industry News

 Tollys Accelerates Development of TLR3 Agonist Candidates for Intravenous Administration in Immuno-oncology | Pharmtech Focus

Tollys Accelerates Development of TLR3 Agonist Candidates for Intravenous Administration in Immuno-oncology

January 31 2022

Tollys, a biopharmaceutical company developing the first anti-cancer immunotherapy based on a synthetic Toll-Like Receptor […]